Docusign vs Insilico Medicine

An AI contract-review tool embedded in Microsoft Word that redlines agreements against playbooks, drafts clause language from plain-language instructions, and answers questions about a contract.

An intelligent agreement repository that uses Docusign Iris to automatically extract key terms, obligations and deadlines from stored contracts and make the portfolio searchable and reportable.

Contract lifecycle management application filed under Docusign IAM: it generates contracts from dynamic templates and uses AI to flag non-compliant clauses, suggest approved language and draft new clauses, runs AI-assisted review, negotiation and summarisation, extracts key terms automatically and answers questions over the repository, all driven by Docusign's Iris AI engine. Sold through sales only.

Family of AI-powered identity-verification and authentication products, using AI-enabled document and biometric liveness checks to validate signer identity, with certified-agent review for inconclusive cases.

No-code builder for agreement workflows that connects intake, document generation, conditional routing and signature steps and syncs data with CRM, procurement, storage and HR systems; Docusign's AI enters through agents that can be dropped into a workflow 'to handle dynamic, judgement-based tasks'. Included in every Docusign IAM plan, with a per-plan cap on the number of workflows.

Intelligent Agreement Management platform built around Iris, Docusign's AI that reads a customer's contracts and surfaces obligations, risks and renewal dates, plus an Agreement Manager and Workflow Builder for acting on what it finds.

Docusign's agreement-AI layer that extracts data from contracts, surfaces risk and renewal insights, and powers the assistant and agents across the IAM platform.

AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.

Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.

AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.

Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.

Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.

AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base.

End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.